Characteristics of adverse events of endocrine therapies among older patients with breast cancer
- 14 Downloads
To clarify the profile of adverse events from endocrine therapies in older patients.
We surveyed 15 subjective symptoms including hot flashes, sweating, knuckle stiffness, knee/shoulder joint pain, limb numbness, lethargy, forgetfulness, depressive state, irritated state, genital bleeding, leukorrhea increase, vaginal dryness, bone fracture, and weight gain by a questionnaire among 2044 patients over 55 years old (total number of answered sheets, 8875) and compared the results according to age (56–69 years old vs. ≥ 70 years old) and type of therapy (aromatase inhibitors (AIs) vs. selective estrogen receptor modulators (SERMs)). Among patients 56–69 years old, 6093 and 314 responses were from patients treated with AIs (1477 patients) and SERMs (123 patients), respectively, and 2292 and 176 responses were from those ≥ 70 years old treated with AIs (581 patients) and SERMs (51 patients), respectively.
In patients ≥ 70 years old, sweating, knuckle stiffness, knee/shoulder joint pain, limb numbness, and lethargy were significantly more frequent/severe with AIs than with SERMs. In those aged 56–69, knuckle stiffness and vaginal dryness were significantly more frequent with AIs than with SERMs, but the opposite occurred for hot flashes, leukorrhea increase, genital bleeding, and weight gain.
Among patients ≥ 70 years old, many symptoms were significantly more frequent/severe with AIs than with SERMs, compared with those aged 56–69, which suggests a difference in the profile of adverse events according to the type of endocrine therapy and the patient’s age. It is important to consider the benefits and risks of each treatment to optimize endocrine therapy for older patients.
KeywordsAromatase inhibitor Endocrine therapy Older Tamoxifen Questionnaire Postmenopausal
We thank all the stuff of Breast Oncology Center, Cancer Institute Hospital for their great help.
This study was supported by MEXT/JSPS KAKENHI grant number 16K08660 and the Japanese Foundation for Multidisciplinary Treatment of Cancer.
Compliance with ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Conflict of interest
The authors have nothing to declare regarding this work. Dr. Saji reports grants and personal fees from Eisai, grants and personal fees from Chugai, grants and personal fees from AstraZeneca, grants and personal fees from Takeda, grants and personal fees from Novartis, grants and personal fees from Taiho, grants and personal fees from Nihon Kayaku, grants from Ono, personal fees from KyowaHakko-Kirin, personal fees from Pfizer, and personal fees from Daiichi Sankyo, outside the submitted work. Dr. Ohno reports grants and personal fees from Chugai, grants and personal fees from Taiho, grants and personal fees from Eisai, grants from Daiichi Sankyo, personal fees from AstraZeneca, personal fees from KyowaHakko-kirin, personal fees from Pfizer, and personal fees from Novartis, outside the submitted work.
- 1.Miller WR, Hawkins RA, Forrest AP (1982) Significance of aromatase activity in human breast cancer. Cancer Res 42:3365s–3368sGoogle Scholar
- 2.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thurlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386:1341–1352CrossRefGoogle Scholar
- 6.Skafar DF, Xu R, Morales J, Ram J, Sowers JR (1997) Clinical review 91: female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab 82:3913–3918Google Scholar
- 9.Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Puglisi F, Pavesi L, Parmar V, Regan MM, Pagani O, Fleming GF, Francis PA, Price KN, Coates AS, Gelber RD, Goldhirsch A, Walley BA (2015) Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol 16:848–858CrossRefGoogle Scholar
- 13.Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, Coombes RC, Hall E (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24:910–917CrossRefGoogle Scholar
- 15.Maunsell E, Goss PE, Chlebowski RT, Ingle JN, Ales-Martinez JE, Sarto GE, Fabian CJ, Pujol P, Ruiz A, Cooke AL, Hendrix S, Thayer DW, Rowland KM, Dube P, Spadafora S, Pruthi S, Lickley L, Ellard SL, Cheung AM, Wactawski-Wende J, Gelmon KA, Johnston D, Hiltz A, Brundage M, Pater JL, Tu D, Richardson H (2014) Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol 32:1427–1436CrossRefGoogle Scholar
- 17.Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE (2008) Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 26:1956–1964CrossRefGoogle Scholar
- 19.van de Water W, Bastiaannet E, Hille ET, Meershoek-Klein Kranenbarg EM, Putter H, Seynaeve CM, Paridaens R, de Craen AJ, Westendorp RG, Liefers GJ, van de Velde CJ (2012) Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis. Oncologist 17:55–63CrossRefGoogle Scholar
- 20.van de Water W, Markopoulos C, van de Velde CJ, Seynaeve C, Hasenburg A, Rea D, Putter H, Nortier JW, de Craen AJ, Hille ET, Bastiaannet E, Hadji P, Westendorp RG, Liefers GJ, Jones SE (2012) Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA 307:590–597Google Scholar
- 21.Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn H, Thurlimann B, St Gallen Int Expert Consensus (2017) De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 28:1700–1712CrossRefGoogle Scholar
- 23.Saji S, Takada M, Honma N, Masuda N, Yamamoto Y, Kuroi K, Yamashita H, Ohno S, Ueno T, Toi M (2012) Serum concentration of estrone (E1), not estradiol (E2), is the independent predictive factor of response to neo-adjuvant exemestane treatment in postmenopausal. Breast Cancer Patients: Jfmc 34-0601 Tr 23:104–104Google Scholar
- 27.Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR (2006) Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: insights into the structural determinants favoring a differential subtype binding. Endocrinology 147:4132–4150CrossRefGoogle Scholar
- 30.de la Torre Valdovinos B, Duenas Jimenez JM, Estrada IJ, Banuelos Pineda J, Franco Rodriguez NE, Lopez Ruiz JR, Osuna Carrasco LP, Candanedo Arellano A, Duenas Jimenez SH (2016) Tamoxifen promotes axonal preservation and gait locomotion recovery after spinal cord injury in cats. J Vet Med 2016:9561968Google Scholar